Meeting
2013 ASCO Annual Meeting
A first-in-human phase I study of CZ48, a lactone ring protected oral camptothecin, in patients with advanced solid tumors.
Authors
Devalingam Mahalingam
Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX
Devalingam Mahalingam , Montaser F. Shaheen , John Sarantopoulos , Steven Weitman , Beppino C. Giovanella , Zhisong Cao , Douglas Coil , Constantine Markides , Lucy Liu , Claire F. Verschraegen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT00947739
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2578)
DOI
10.1200/jco.2013.31.15_suppl.2578
Abstract #
2578
Poster Bd #
6F
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2022 ASCO Annual Meeting
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
First Author: Liza C Villaruz